Scientific Program

Day 1

Vaccine & Immunization
Chair
Speaker
  • Nanoparticles, as antigen delivery system of antigens, for a nasal vaccine against toxoplasmosis
    Speaker
    Didier Betbeder
    University Lille 2
    France
    Biography

    Pr Didier Betbeder has 25 years of experience in drug delivery using colloids, ranging from basic research to clinical studies. Working with the World Health Organisation he obtained his PhD in 1988 on drug targeting to treat sleeping sickness, before spending two years as a post-doctoral fellow at the University of Warwick (England). He was then engaged by Bio- Europe, a company specialising in biocatalysis, before joining Biovector Therapeutics (France) as Research director from 1992 – 2001. He is Professor at the University of Artois and Lille 2 since 2001, his research focusing on the development of innovative nanoparticles based on polysaccharide and phospholipid assemblies. He developed from research to clinical development a technology based on polysaccharide nanoparticles supporting a phospholipid bi-layer, these nanoparticles were found to have a strong mucosal residence and good candidates for vaccine applications.

    Abstract

    Nanoparticles can act as adjuvant as they are able to deliver antigens to immune cells, therefore increasing their immunogenicity. A better knowledge of the mechanisms of interaction with the biological fluids and cells is necessary to fully understand their potential as delivery systems. Most of pathogens access to human body through mucosal, therefore it is interesting to mimic infection to elicit a protective immunity. In this presentation we will describe the mechanisms of interaction of nanoparticles with airway mucosa cells and their ability to deliver antigens within cells. Furthermore, their interest in term of antigen formulation, stability and efficacy against Toxoplasma gondii infection will be presented.

  • Enhancing antibody serodiagnosis on peptide microarrays using a controlled multipresentation strategy
    Speaker
    Marina Cretich
    National Research Council, Institute of Chemistry of Molecular Recognition (ICRM-CNR)
    Italy
    Abstract

    Here we present a workflow enabling the rapid delivery of efficient immunoassays for different diagnostics contexts which expands the current limits of peptide-based serodiagnosis on microarrays. Our strategy starts from the use of computational tools for accurate immune-reactive peptide design; exploit chemo-selective strategies for optimal probes presentation on sensing surfaces using clickable polymeric coatings and finally generate peptide chips for fluorescence microarrays and SPR imaging. We will show how the rigorous control of probe design, orientation and surface density enabled by our platform positively impacts the diagnostic accuracy of antibody detection in serum of Burkholderia infected patients. Furthermore, we will compare different strategies of peptide multiple presentation to increase immunoreactivity in the context of allergy screening and for functional mimicking of discontinuous epitopes of NS1 protein for Zika virus diagnosis.

  • Characteristics of montanide™ ISA 51 VG adjuvant designed for therapeutic cancer vaccines
    Speaker
    Maria Lazaro
    Seppic
    France
    Biography

    Maria Lazaro is a Pharmacist from Complutense University of Madrid. He/She(according to the author’s gender) holds advanced master’s in Biotechnology and Pharmaceutical Management works for Seppic in Human Biologicals department (adjuvants for vaccines and excipients for injectables ) since 2012.

    Abstract

    Therapeutic cancer vaccines are one interesting alternative to treat cancer by active immunotherapy. The use of well-defined overexpressed tumor antigens is linked with weak and short term immune response. To improve the immune response induced antigens may be associated with enhancers such as adjuvants. Water-in-oil (W/O) emulsions such as MontanideTM ISA 51 VG represent an interesting option for immunotherapy vaccines for which potent adjuvants are required. CIMAVAX-EGF vaccine to treat cancer has already been authorized in Cuba and many others latin american countries, it’s also in late state in Europe and Asian countries which efficacy has been largely proven in patients suffering from lung cancer (NSCLC). Vaccines based on Montanide™ ISA 51 VG interestingly enhance the immune response thanks to a depot effect conferred by this kind of adjuvant at the injection site. This renders a danger signal that increases and prolongs the interaction with antigen presenting cells. These interactions lead to an enhanced CD8+ and CD4+ activation and promote production of IFN, TNF?, IL-2. Additionally, the use of adjuvant enhances the memory T-cells, in particular the central memory T-cells. Taken together, these results show that vaccines based on Montanide™ ISA 51 VG can induce a potent specific cytotoxic T response and a significant increase in antibody titers with the development of polarized Th1

Day 2

Immunology of Infectious Diseases
Chair
Speaker
  • Immune responses of mice immunized with HBsAg formulated in naloxone/alum mixture: Comparison to fendrix vaccine
    Speaker
    Mohammad Hossein Yazdi
    Tehran University of Medical Sciences, Tehran, Iran
    Iran
    Biography

    Mohammad Hossein Yazdi got his PhD in the field of Pharmaceutical Biotechnology by 2014 from Tehran University of Medical Sciences, School of Pharmacy. His PhD work was about cancer treatment in particular by immunotherapy. He is now Assistant Professor at Biotechnology Research Center and Recombinant Vaccine Research Center of Tehran University of Medical Sciences and pursues his interest in both vaccine and immunotherapy of cancer and infectious diseases. He has published more than 30 papers in reputed journals and has been serving as senior lecturer of advanced immunology and immunotherapy at Tehran University of Medical Sciences.

    Abstract

    Hepatitis B virus can cause cirrhosis of the liver and hepatocellular carcinoma. Due to the lack of sufficient immune response in whole population, several researches are being done to improve the efficacy of Alum based HBV vaccine. Here, naloxone/alum mixture as adjuvant was used for the HBsAg vaccine and immune parameters evaluated in immunized mice. In this study the effect of naloxone/alum mixture for the HBsAg vaccine has been investigated and compared to Fendrix vaccine. Female Balb/c mice were vaccinated at day 0, 14 and 28 with, alum based vaccine or naloxone/alum mixture vaccine in different doses. Naloxone/alum vaccine groups received the dose 3, 6 or 10 mg/kg of naloxone in the vaccine formulation. One group received routine HBsAg alum vaccine and a group received Fendrix vaccine. Some groups received naloxone plus HBsAg without alum and a group received HBsAg without adjuvant. PBS, naloxone and alum were also injected into the control groups separately. Finally, the naloxone/alum formulated vaccine compared with the Fendrix and routine alum based vaccine regarding to the levels of total anti-HBS antibody, IFN-?, IL-4, IgG1 and IgG2a and the level of lymphocyte proliferation.The level of total anti-HBS antibody in Naloxone formulated vaccine was comparable with Fendrix. Meanwhile, IFN-?/IL-4 ratio level was significantly higher in Naloxone formulated vaccine groups versus mere vaccine group. IgG2a was also higher in the naloxone formulated vaccine groups. These data showed that naloxone/alum mixture has ability to shift the immune response toward Th1 pattern, which more potentiate the immunity against infections.

  • Temperature data analysis of the vaccine cold chain system in northern part of Thailand
    Speaker
    Kannika Thiankhanithikun
    Chiang Mai University
    Thailand
    Biography

    Kannika Thiankhanithikun is Faculty of Pharmacy in Chiang Mai University Thailand.

    Abstract

    Vaccines are temperature-sensitive biological preparations, 2-8°C or cold chain period were the appropriate range. The change of the temperature during transport system might be effect to vaccines quality assurance. This descriptive study was to analyze the data temperature of vaccine in cold chain system. We aimed to find the factor that effected to the change of vaccine’s temperature before used, such as area of vaccine transport, seasonal and type of health care unit. Temperature data of DPT- HB vaccine that used in National Health Security Office (NHSO) region 1, included 8 provinces in northern part of Thailand were analyzed. The temperature data were collected by computerized data logger and analyzed by SPSS for window version 17.0 and logtag analyzer program. The result showed that, from 323 health care units in fiscal year 2011, DPT-HB vaccine temperature had lower than 2°C at 86.9% and upper than 8°C at 90.4%. Type of health care unit and seasonal didn’t affect to vaccine temperature control, significantly. In fiscal year 2012, DPT-HB vaccine temperature from 1,399 health care units showed that lower than 2°C at 78.5% and upper than 8°C at 92.5%. Type of health care unit didn’t affect to vaccine’s temperature control following the World Health Organization criteria but the seasonal had significant effect to vaccine’s temperature control. The study also found that most of the health care worker did not set the computerize data logger follow the handout of the company. Based on the study results, adequate equipment, provide training and supervision about new and current computerize data logger were recommended to support to maximize the efficacy and effectiveness of vaccine and cold chain monitoring in health care unit

  • Assessment of the Risk of Contamination with BVD Virus in Preparation of Veterinary Rabies Vaccine
    Speaker
    Masoud Ghorbani
    Pasteur Institute of Iran
    Iran
    Biography

    Masoud Ghorbani has received his Doctor of Veterinary Medicine degree from the University of Tehran in 1985 and moved to Ottawa, Ontario, Canada in 1990. He enrolled in his PhD, program at the Department of Biochemistry at the University of Ottawa and was graduated with a PhD degree. He has extensive experience on developing innovative peptide and DNA vaccines against HIV and influenza viruses in animal models including mice, ferrets, and monkeys while he was appointed as a Senior Research Scientist at the Variation Biotechnologies Inc. in Ottawa, Ontario, Canada. He has also worked at the Department of Molecular Biology and Microbiology, Case Western Reserve University, Cleveland, Ohio, USA (2003-2004) as well as Children’s Hospital of Eastern Ontario, Ottawa, Canada (CHEO) (2000-2003) as a Senior Research Associate. In 2008, he returned back to Tehran and started working at Pasteur Institute of Iran as an Assistant Professor. His current projects are mainly focused on quality control of rabies vaccine production as well as the development of new version of an oral vaccine for the use in animals.

    Abstract

    The absence of contamination is necessary for all veterinary vaccine. However, the quality control does not always imply that vaccines are not contaminated. One of the prominent vaccine contaminations is the presence of a small amount of bovine viral diarrhea virus (BVDV) which can infect vaccinated animals. In case of preparation of rabies vaccine, the target animals dogs, and cattle especially in a high-risk environment. The contamination is sometimes inevitable since the vaccine is prepared in animal cultured cells that required fetal calf serum (FCS) as well as bovine serum albumin (BSA). Therefore, a constant quality control is required during all steps of vaccine preparation to determine the contamination with BVD virus. We, therefore, carried out in vitro experiments to determine the BVDV using both PCR and ELISA techniques. Samples of tissue culture cells of five different batches containing fetal calf serum were collected. Randomly, samples of BSA and FCS used for vaccine preparation were collected as well. A nested PCR carried out using specific primers for BVDV. An inactivated BVD virus was used as the positive control. The ELISA test was performed using an IDEXX BVDV Ag/serum plus kit. Fortunately, neither of RT-PCR or ELISA test results was positive with BVD virus during all steps of vaccine preparation. This could be because of both recruiting high-quality reagents and serums for tissue culture and inactivation of rabies virus with beta-propiolactone as a recommended agent for viral inactivation. Based on the results of our experiments, we concluded that a rabies vaccine preparation in our facility is safe enough for use in cattle as well as other animals.

Mail us at

Drop us an email for Program enquiry
eurovaccines@alliedconferences.net
Sponsors/Exhibiting/Advertising
eurovaccines@alliedconferences.net
General Queries
eurovaccines@alliedconferences.net
More details about sponsorship:sponsors@alliedacademies.com

Terms and Conditions

 Responsibility

The organizers holds no responsibilities or liabilities of the personal articles of attendees at the venue against any kind of theft, lost, damage, due to any reason whatsoever. Delegates are entirely responsible for the safety of their own belongings.

 

Insurance

No insurance, of any kind, is included along with the registration in any of the events of the organization.


Transportation

Please note that transportation and parking is the responsibility of the registrant, Allied Academies will not be liable for any actions howsoever related to transportation and parking.

 

Press/Media

Press permission must be obtained from Allied Academies Conference Organizing Committee prior to the event. The press will not quote speakers or delegates unless they have obtained their approval in writing. The Allied Academies is an objective third-party nonprofit organization and this conference is not associated with any commercial meeting company.


Requesting an Invitation Letter

For security purposes, letter of invitation will be sent only to those individuals who had registered for the conference after payment of complete registration fee. Once registration is complete, please contact vaccinecongress@alliedmeetings.com to request for a personalized letter of invitation, if not received until one month before the scheduled date of event.

All the bank charges applicable during refund will be deducted from the account of participant.


Cancellation Policy

All cancellations or modifications of registration must be made in writing to finance@alliedacademies.com

If, due to any reason, Allied academies postpone an event on the scheduled date, the participant is eligible for a credit of 100% of the registration fee paid. This credit shall only be used for another event organized by Allied academies within period of one year from the date of rescheduling. 

Postponement of event

If, due to any reason, Allied academies postpone an event and the participant is unable or unwilling to attend the conference on rescheduled dates, he/she is eligible for a credit of 100% of the registration fee paid. This credit shall only be used for another event organized by Allied academies within period of one year from the date of rescheduling.

Transfer of registration

All registrations, after payment of complete registration fee, are transferable to other persons from the same organization, if in case the person is unable to attend the event. Request for transfer of registration must be made by the registered person in writing to finance@alliedacademies.com. Details must include the full name of replaced new registrant, their title, contact phone number and email address. All other registration details will be assigned to the new person unless otherwise specified.

Registration can be transferred to one conference to another conference of Allied academies if the person is unable to attend one of conferences.

However, Registration cannot be transferred if intimated within 14 days of respective conference.

The transferred registrations will not be eligible for Refund.

This cancellation policy was last updated on April 04, 2015.


Visa Information

Keeping in view of increased security measures, we would like to request all the participants to apply for Visa as soon as possible.

Allied academies will not directly contact embassies and consulates on behalf of visa applicants. All delegates or invitees should apply for Business Visa only.

Important note for failed visa applications: Visa issues are not covered under the cancellation policy of Allied academies, including the inability to obtain a visa.


Refund Policy:

If the registrant is unable to attend, and is not in a position to transfer his/her participation to another person or event, then the following refund policies apply:

Keeping in view of advance payments towards Venue, Printing, Shipping, Hotels and other overhead charges, following Refund Policy Orders are available:

  • Before 60 days of the conference: Eligible for Full Refund after deduction of $100 towards service Fee.
  • Within 60-30 days of Conference: Eligible for 50% of payment Refund
  • Within 30 days of Conference: Not eligible for Refund
  • E-Poster Payments will not be refunded.

Accommodation Cancellation Policy:

Accommodation Service Providers (Hotels) have their own cancellation policies which are applicable when cancellations are made less than 30 days prior to arrival. If in case the registrant wishes to cancel or amend the accommodation, he/ she is expected to inform the organizing authorities on a prior basis. Allied academies will advise the registrant to ensure complete awareness about the cancellation policy of your accommodation provider, prior to cancellation or modification of their booking.

 

Copyright © 2018-2019 Allied Academies, All Rights Reserved.